Oct. 03, 2024

JCR Affirmed AA-/Stable and J-1+ on Takeda Pharmaceutical

Jul. 09, 2024

JCR Assigned A Rating to Subordinated Loan of Takeda Pharmaceutical

Jun. 07, 2024

JCR Assigned A Rating to Subordinated Bonds of Takeda Pharmaceutical

Apr. 15, 2024

JCR Assigned Preliminary A Rating to Subordinated Bonds of Takeda Pharmaceutical

Sep. 08, 2023

JCR Assigned Preliminary AA- Rating to Shelf Registration of Takeda Pharmaceutical

Jul. 11, 2023

JCR Affirmed AA-/Stable and J-1+ on Takeda Pharmaceutical

Dec. 15, 2022

Takeda Pharmaceutical Acquires New Drug Candidate for USD 4 Billion - Limited Impact on Rating

Oct. 03, 2022

JCR Upgraded Rating on Takeda Pharmaceutical to AA-/Stable and J-1+

Jun. 15, 2022

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2022

Oct. 08, 2021

JCR Assigned A+ Rating to Bonds of Takeda Pharmaceutical

Sep. 08, 2021

JCR Assigned Preliminary A+ Rating to Shelf Registration of Takeda Pharmaceutical

Jun. 01, 2021

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2021

May. 27, 2021

JCR Affirmed A+/Stable, A- and J-1 on Takeda Pharmaceutical

Jun. 17, 2020

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2020

May. 27, 2020

JCR Affirmed A+/Stable, A- and J-1 on Takeda Pharmaceutical

Jun. 25, 2019

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2019

May. 31, 2019

JCR Assigned A- Rating to Subordinated Bonds of Takeda Pharmaceutical

May. 15, 2019

Earnings forecasts for FY2019 Announced by Takeda Pharmaceutical - Within the Scope of Assumption and No Need for Rating Change

May. 10, 2019

Divestitures of Non-core Assets by Takeda Pharmaceutical - Assumed as Before and Limited Impact on Rating

Feb. 15, 2019

JCR Assigned Preliminary A- Rating to Subordinated Bonds of Takeda Pharmaceutical

Feb. 15, 2019

JCR Assigned J-1 Rating to CP of Takeda Pharmaceutical

Jan. 31, 2019

JCR Assigned A+/Stable Long-term Issuer Rating to Takeda Pharmaceutical